Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2015

View Archived Issues

Osaka University starts phase I/II trial of CNT-01 in patients with idiopathic TGCV

Tohoku University, Gunma University and Fuso disclose OPN production inhibitors

Glycemic improvements similar with omarigliptin and sitagliptin in patients with type 2 diabetes

Pediatric schistosomiasis candidate L-praziquantel safe in phase I study in healthy volunteers

New mutation in HNF1B identified in patient with maturity-onset diabetes of the young type 5

Rat forelimb allotransplantation model enables assessment of function

FDA grants fast track designation to Alcobra's metadoxine extended release

Transgenic pigs used to model gestational diabetes

Glide Technologies and Cilian to develop novel solid dose recombinant influenza vaccine

Palatin Technologies and Richter terminate license agreement for bremelanotide

Saniona reports data supporting the use of Tesomet in type 2 diabetes, plans proof-of-concept study

Artificially designed peptide inhibits HIV fusion with improved pharmacological properties

AcelRx sells portion of Zalviso royalty stream to PDL BioPharma

Phase III induction trials of tofacitinib in ulcerative colitis meet primary endpoints

Companies receive funding to advance Ebola programs

Harbour Antibodies signs new licenses to transgenic mouse platforms

Roche reports compounds for the treatment of hepatitis B

Gilead reports topline results from four phase III studies of sofosbuvir/velpatasvir for HCV

Aerie initiates phase III trial of Roclatan

Akari Therapeutics formed to develop treatments for diseases involving complement C5

Plexxikon discloses c-Kit inhibitors

Clinical effect of K-877 may be superior to fibrate drugs on the market

Taro launches Keveyis for primary hyperkalemic and hypokalemic periodic paralysis

Pharmaxis reports phase I results for PXS-4728A

LFB's IVIg Iqymune approved in U.K. and Denmark

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...